{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:36:32Z","timestamp":1788554192512,"version":"build-2803163510"},"reference-count":84,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100001824","name":"Ministry of Education of the Czech Republic","doi-asserted-by":"publisher","award":["LO1305"],"award-info":[{"award-number":["LO1305"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-17-0373"],"award-info":[{"award-number":["APVV-17-0373"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Slovak Research and Development Agency","doi-asserted-by":"publisher","award":["APVV-17-0318"],"award-info":[{"award-number":["APVV-17-0318"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003194","name":"Agency of Ministry of Education, Science, Research and Sport of the Slovak Republic","doi-asserted-by":"publisher","award":["VEGA 1\/0040\/17"],"award-info":[{"award-number":["VEGA 1\/0040\/17"]}],"id":[{"id":"10.13039\/501100003194","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2019,8,26]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>The Angiotensin-I converting enzyme (ACE) is one of the most important components of the renin-angiotensin-aldosterone system controlling blood pressure and renal functions. Inhibitors of ACE are first line therapeutics used in the treatment of hypertension and related cardiovascular diseases. Somatic ACE consists of two homologous catalytic domains, the C- and N-domains. Recent findings have shown that although both domains are highly homologous in structure, they may have different physiological functions. The C-domain is primarily involved in the control of blood pressure, in contrast to the N-domain that is engaged in the regulation of hematopoietic stem cell proliferation. The currently available ACE inhibitors have some adverse effects that can be attributed to the non-selective inhibition of both domains. In addition, specific Ndomain inhibitors have emerged as potential antifibrotic drugs. Therefore, ACE is still an important drug target for the development of novel domain-selective drugs not only for the cardiovascular system but also for other systems.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>Detailed structural information about interactions in the protein-ligand complex is crucial for rational drug design. This review highlights the structural information available from crystallographic data which is essential for the development of domain selective inhibitors of ACE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Over eighty crystal complexes of ACE are placed into the Protein Database. An overview of X-ray ACE complexes with various inhibitors in C- and N-domains and an analysis of their binding mode have given mechanistic explanation of the structural determinants of selective ligand binding. In addition, ACE domain selective inhibitors with dual modes of action in complexes with ACE are also discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Selectivity of ACE inhibitors for the N- and C-domain is controlled by subtle differences in the amino-acids forming the active site. Reported studies of crystal complexes of inhibitors in the C- and N-domains revealed that most selective inhibitors interact with non-conserved amino-acids between domains and have distinct interactions with the residues in the S2 and S2\u2019 subsites of the ACE catalytic site. Moreover, unusual binding of the second molecule of inhibitors in the binding cavity opens new possibilities of exploiting more distant regions of the catalytic center in structure-based design of novel drugs.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573406415666190514081132","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T07:43:07Z","timestamp":1557819787000},"page":"574-587","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Advances in Structural Biology of ACE and Development of Domain Selective ACE-inhibitors"],"prefix":"10.2174","volume":"15","author":[{"given":"M\u00e1ja","family":"Polakovi\u010dov\u00e1","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-83232 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Jamp\u00edlek","sequence":"additional","affiliation":[{"name":"Department of Analytical Chemistry, Faculty of Natural Sciences, Comenius University, Ilkovicova 6, SK-84215 Bratislava, Slovakia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1586\/erc.12.63","volume":"10","author":"Epstein B.J.","year":"2012","unstructured":"Epstein B.J.; Leonard P.T.; Shah N.K.; The evolving landscape of RAAS inhibition: From ACE inhibitors to ARBs, to DRIs and\u2009beyond. Expert Rev Cardiovasc Ther 2012,10(6),713-725","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/hr.2009.184","volume":"33","author":"Hanif K.","year":"2010","unstructured":"Hanif K.; Bid H.K.; Konwar R.; Reinventing the ACE inhibitors: Some old and new implications of ACE inhibition. Hypertens Res 2010,33(1),11-21","journal-title":"Hypertens Res"},{"key":"ref=3","first-page":"461","volume":"66","author":"Bicket D.P.","year":"2002","unstructured":"Bicket D.P.; Using ACE inhibitors appropriately. Am Fam Physician 2002,66(3),461-468","journal-title":"Am Fam Physician"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","volume":"10","author":"Morimoto T.","year":"2004","unstructured":"Morimoto T.; Gandhi T.K.; Fiskio J.M.; Seger A.C.; So J.W.; Cook E.F.; Fukui T.; Bates D.W.; An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004,10(4),499-509","journal-title":"J Eval Clin Pract"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1016\/S0140-6736(02)08914-6","volume":"359","author":"Adam A.","year":"2002","unstructured":"Adam A.; Cugno M.; Molinaro G.; Perez M.; Lepage Y.; Agostoni A.; Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002,359(9323),2088-2089","journal-title":"Lancet"},{"key":"ref=6","first-page":"423","volume":"40","author":"Yeo W.W.","year":"1995","unstructured":"Yeo W.W.; Chadwick I.G.; Kraskiewicz M.; Jackson P.R.; Ramsay L.E.; Resolution of ACE inhibitor cough: Changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and Substance-P. Br J Clin Pharmacol 1995,40(5),423-429","journal-title":"Br J Clin Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"9386","DOI":"10.1073\/pnas.85.24.9386","volume":"85","author":"Soubrier F.","year":"1988","unstructured":"Soubrier F.; Alhenc-Gelas F.; Hubert C.; Allegrini J.; John M.; Tregear G.; Corvol P.; Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci USA 1988,85(24),9386-9390","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0165-6147(00)01994-5","volume":"23","author":"Turner A.J.","year":"2002","unstructured":"Turner A.J.; Hooper N.M.; The angiotensin-converting enzyme gene family: Genomics and pharmacology. Trends Pharmacol Sci 2002,23(4),177-183","journal-title":"Trends Pharmacol Sci"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"15377","DOI":"10.1016\/S0021-9258(18)98626-6","volume":"266","author":"Hubert C.","year":"1991","unstructured":"Hubert C.; Houot A.M.; Corvol P.; Soubrier F.; Structure of the Angiotensin I-Converting Enzyme gene. Two alternate promoters correspond to evolutionary steps of a duplicated gene. J Biol Chem 1991,266(23),15377-15383","journal-title":"J Biol Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.coph.2010.11.001","volume":"11","author":"Bernstein K.E.","year":"2011","unstructured":"Bernstein K.E.; Shen X.Z.; Gonzalez-Villalobos R.A.; Billet S.; Okwan-Duodu D.; Ong F.S.; Fuchs S.; Different in vivo functions of the two catalytic domains of angiotensin-converting enzyme (ACE). Curr Opin Pharmacol 2011,11(2),105-111","journal-title":"Curr Opin Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1161\/01.HYP.0000151323.93372.f5","volume":"45","author":"van Esch J.H.","year":"2005","unstructured":"van Esch J.H.; Tom B.; Dive V.; Batenburg W.W.; Georgiadis D.; Yiotakis A.; van Gool J.M.; de Bruijn R.J.; de Vries R.; Danser A.H.; Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction. Hypertension 2005,45(1),120-125","journal-title":"Hypertension"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"13398","DOI":"10.1016\/S0021-9258(18)42224-7","volume":"267","author":"Wei L.","year":"1992","unstructured":"Wei L.; Clauser E.; Alhenc-Gelas F.; Corvol P.; The two homologous domains of human angiotensin I-converting enzyme interact differently with competitive inhibitors. J Biol Chem 1992,267(19),13398-13405","journal-title":"J Biol Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1161\/01.RES.0000081593.33848.FC","volume":"93","author":"Georgiadis D.","year":"2003","unstructured":"Georgiadis D.; Beau F.; Czarny B.; Cotton J.; Yiotakis A.; Dive V.; Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: Insights from selective inhibitors. Circ Res 2003,93(2),148-154","journal-title":"Circ Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0006-291X(03)01363-9","volume":"308","author":"Fernandez J.H.","year":"2003","unstructured":"Fernandez J.H.; Hayashi M.A.; Camargo A.C.; Neshich G.; Structural basis of the lisinopril-binding specificity in N- and C-domains of human somatic ACE. Biochem Biophys Res Commun 2003,308(2),219-226","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1074\/jbc.270.8.3656","volume":"270","author":"Rousseau A.","year":"1995","unstructured":"Rousseau A.; Michaud A.; Chauvet M.T.; Lenfant M.; Corvol P.; The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J Biol Chem 1995,270(8),3656-3661","journal-title":"J Biol Chem"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1016\/S0021-9258(18)31543-6","volume":"266","author":"Wei L.","year":"1991","unstructured":"Wei L.; Alhenc-Gelas F.; Corvol P.; Clauser E.; The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. J Biol Chem 1991,266(14),9002-9008","journal-title":"J Biol Chem"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1515\/hsz-2012-0127","volume":"393","author":"Sharma R.K.","year":"2012","unstructured":"Sharma R.K.; Douglas R.G.; Louw S.; Chibale K.; Sturrock E.D.; New ketomethylene inhibitor analogues: Synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme. Biol Chem 2012,393(6),485-493","journal-title":"Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1161\/01.HYP.31.4.912","volume":"31","author":"Deddish P.A.","year":"1998","unstructured":"Deddish P.A.; Marcic B.; Jackman H.L.; Wang H.Z.; Skidgel R.A.; Erd\u00f6s E.G.; N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: Angiotensin-(1-7) and keto-ACE. Hypertension 1998,31(4),912-917","journal-title":"Hypertension"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1460-9568.2005.03912.x","volume":"21","author":"Oba R.","year":"2005","unstructured":"Oba R.; Igarashi A.; Kamata M.; Nagata K.; Takano S.; Nakagawa H.; The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci 2005,21(3),733-740","journal-title":"Eur J Neurosci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1111\/febs.13647","volume":"283","author":"Larmuth K.M.","year":"2016","unstructured":"Larmuth K.M.; Masuyer G.; Douglas R.G.; Schwager S.L.; Acharya K.R.; Sturrock E.D.; Kinetic and structural characterization of amyloid-\u03b2 peptide hydrolysis by human angiotensin-1-converting enzyme. FEBS J 2016,283(6),1060-1076","journal-title":"FEBS J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"H1226","DOI":"10.1152\/ajpheart.00305.2007","volume":"294","author":"Sharma U.","year":"2008","unstructured":"Sharma U.; Rhaleb N.E.; Pokharel S.; Harding P.; Rasoul S.; Peng H.; Carretero O.A.; Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. Am J Physiol Heart Circ Physiol 2008,294(3),H1226-H1232","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00109-013-1051-z","volume":"91","author":"Gonzalez-Villalobos R.A.","year":"2013","unstructured":"Gonzalez-Villalobos R.A.; Shen X.Z.; Bernstein E.A.; Janjulia T.; Taylor B.; Giani J.F.; Blackwell W.L.; Shah K.H.; Shi P.D.; Fuchs S.; Bernstein K.E.; Rediscovering ACE: novel insights into the many roles of the angiotensin-converting enzyme. J Mol Med (Berl) 2013,91(10),1143-1154","journal-title":"J Mol Med (Berl)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.112.006809","volume":"65","author":"Bernstein K.E.","year":"2012","unstructured":"Bernstein K.E.; Ong F.S.; Blackwell W.L.; Shah K.H.; Giani J.F.; Gonzalez-Villalobos R.A.; Shen X.Z.; Fuchs S.; Touyz R.M.; A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 2012,65(1),1-46","journal-title":"Pharmacol Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.phrs.2018.07.006","volume":"134","author":"Kumar N.","year":"2018","unstructured":"Kumar N.; Yin C.; The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases. Pharmacol Res 2018,134,268-279","journal-title":"Pharmacol Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1124\/mol.51.6.1070","volume":"51","author":"Michaud A.","year":"1997","unstructured":"Michaud A.; Williams T.A.; Chauvet M.T.; Corvol P.; Substrate dependence of angiotensin I-converting enzyme inhibition: captopril displays a partial selectivity for inhibition of N-acetyl-seryl-aspartyl-lysyl-proline hydrolysis compared with that of angiotensin I. Mol Pharmacol 1997,51(6),1070-1076","journal-title":"Mol Pharmacol"},{"key":"ref=26","first-page":"1257","volume":"289","author":"Junot C.","year":"1999","unstructured":"Junot C.; Menard J.; Gonzales M.F.; Michaud A.; Corvol P.; Ezan E.; In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis. J Pharmacol Exp Ther 1999,289(3),1257-1261","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0014-5793(02)02888-0","volume":"522","author":"Voronov S.","year":"2002","unstructured":"Voronov S.; Zueva N.; Orlov V.; Arutyunyan A.; Kost O.; Temperature-induced selective death of the C-domain within angiotensin-converting enzyme molecule. FEBS Lett 2002,522(1-3),77-82","journal-title":"FEBS Lett"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"9496","DOI":"10.1016\/S0021-9258(18)98378-X","volume":"268","author":"Jaspard E.","year":"1993","unstructured":"Jaspard E.; Wei L.; Alhenc-Gelas F.; Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides. J Biol Chem 1993,268(13),9496-9503","journal-title":"J Biol Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nature01370","volume":"421","author":"Natesh R.","year":"2003","unstructured":"Natesh R.; Schwager S.L.; Sturrock E.D.; Acharya K.R.; Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003,421(6922),551-554","journal-title":"Nature"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1007\/s00018-004-4239-0","volume":"61","author":"Sturrock E.D.","year":"2004","unstructured":"Sturrock E.D.; Natesh R.; van Rooyen J.M.; Acharya K.R.; Structure of angiotensin I-converting enzyme. Cell Mol Life Sci 2004,61(21),2677-2686","journal-title":"Cell Mol Life Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1038\/nrd1227","volume":"2","author":"Acharya K.R.","year":"2003","unstructured":"Acharya K.R.; Sturrock E.D.; Riordan J.F.; Ehlers M.R.; Ace revisited: a new target for structure-based drug design. Nat Rev Drug Discov 2003,2(11),891-902","journal-title":"Nat Rev Drug Discov"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/820476","author":"Spyranti Z.","year":"2010","unstructured":"Spyranti Z.; Galanis A.S.; Pairas G.; Spyroulias G.A.; Manessi-Zoupa E.; Cordopatis P.; Synthetic peptides as structural maquettes of Angiotensin-I converting enzyme catalytic sites. Bioinorg Chem Appl 2010","journal-title":"Bioinorg Chem Appl"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"8718","DOI":"10.1021\/bi049480n","volume":"43","author":"Natesh R.","year":"2004","unstructured":"Natesh R.; Schwager S.L.; Evans H.R.; Sturrock E.D.; Acharya K.R.; Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry 2004,43(27),8718-8724","journal-title":"Biochemistry"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.1021\/bi8002605","volume":"47","author":"Watermeyer J.M.","year":"2008","unstructured":"Watermeyer J.M.; Kr\u00f6ger W.L.; O\u2019Neill H.G.; Sewell B.T.; Sturrock E.D.; Probing the basis of domain-dependent inhibition using novel ketone inhibitors of Angiotensin-converting enzyme. Biochemistry 2008,47(22),5942-5950","journal-title":"Biochemistry"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1042\/BJ20100056","volume":"428","author":"Watermeyer J.M.","year":"2010","unstructured":"Watermeyer J.M.; Kr\u00f6ger W.L.; O\u2019Neill H.G.; Sewell B.T.; Sturrock E.D.; Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril. Biochem J 2010,428(1),67-74","journal-title":"Biochem J"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1042\/BJ20102123","volume":"436","author":"Akif M.","year":"2011","unstructured":"Akif M.; Schwager S.L.; Anthony C.S.; Czarny B.; Beau F.; Dive V.; Sturrock E.D.; Acharya K.R.; Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide. Biochem J 2011,436(1),53-59","journal-title":"Biochem J"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1111\/j.1742-4658.2011.08276.x","volume":"278","author":"Akif M.","year":"2011","unstructured":"Akif M.; Masuyer G.; Schwager S.L.; Bhuyan B.J.; Mugesh G.; Isaac R.E.; Sturrock E.D.; Acharya K.R.; Structural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captopril. FEBS J 2011,278(19),3644-3650","journal-title":"FEBS J"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/srep00717","volume":"2","author":"Masuyer G.","year":"2012","unstructured":"Masuyer G.; Schwager S.L.; Sturrock E.D.; Isaac R.E.; Acharya K.R.; Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides. Sci Rep 2012,2,717","journal-title":"Sci Rep"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/febs.12660","volume":"281","author":"Masuyer G.","year":"2014","unstructured":"Masuyer G.; Akif M.; Czarny B.; Beau F.; Schwager S.L.; Sturrock E.D.; Isaac R.E.; Dive V.; Acharya K.R.; Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme. FEBS J 2014,281(3),943-956","journal-title":"FEBS J"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1021\/ml4004588","volume":"5","author":"Kramer G.J.","year":"2014","unstructured":"Kramer G.J.; Mohd A.; Schwager S.L.U.; Masuyer G.; Acharya K.R.; Sturrock E.D.; Bachmann B.O.; Interkingdom pharmacology of Angiotensin-I converting enzyme inhibitor phosphonates produced by actinomycetes. ACS Med Chem Lett 2014,5(4),346-351","journal-title":"ACS Med Chem Lett"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1111\/febs.14421","volume":"285","author":"Cozier G.E.","year":"2018","unstructured":"Cozier G.E.; Schwager S.L.; Sharma R.K.; Chibale K.; Sturrock E.D.; Acharya K.R.; Crystal structures of sampatrilat and sampatrilat-Asp in complex with human ACE - a molecular basis for domain selectivity. FEBS J 2018,285(8),1477-1490","journal-title":"FEBS J"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.1021\/acs.jmedchem.8b01309","volume":"61","author":"Cozier G.E.","year":"2018","unstructured":"Cozier G.E.; Arendse L.B.; Schwager S.L.; Sturrock E.D.; Acharya K.R.; Molecular basis for multiple omapatrilat binding sites within the ACE C-domain: Implications for drug design. J Med Chem 2018,61(22),10141-10154","journal-title":"J Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.jmb.2006.01.048","volume":"357","author":"Corradi H.R.","year":"2006","unstructured":"Corradi H.R.; Schwager S.L.; Nchinda A.T.; Sturrock E.D.; Acharya K.R.; Crystal structure of the N-domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol 2006,357(3),964-974","journal-title":"J Mol Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"35685","DOI":"10.1074\/jbc.M110.167866","volume":"285","author":"Anthony C.S.","year":"2010","unstructured":"Anthony C.S.; Corradi H.R.; Schwager S.L.; Redelinghuys P.; Georgiadis D.; Dive V.; Acharya K.R.; Sturrock E.D.; The N-domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N-domain-specific phosphinic inhibitor, RXP407. J Biol Chem 2010,285(46),35685-35693","journal-title":"J Biol Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1021\/bi700275e","volume":"46","author":"Corradi H.R.","year":"2007","unstructured":"Corradi H.R.; Chitapi I.; Sewell B.T.; Georgiadis D.; Dive V.; Sturrock E.D.; Acharya K.R.; The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. Biochemistry 2007,46(18),5473-5478","journal-title":"Biochemistry"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1042\/CS20130403","volume":"126","author":"Douglas R.G.","year":"2014","unstructured":"Douglas R.G.; Sharma R.K.; Masuyer G.; Lubbe L.; Zamora I.; Acharya K.R.; Chibale K.; Sturrock E.D.; Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors. Clin Sci (Lond) 2014,126(4),305-313","journal-title":"Clin Sci (Lond)"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"13742","DOI":"10.1038\/srep13742","volume":"5","author":"Masuyer G.","year":"2015","unstructured":"Masuyer G.; Douglas R.G.; Sturrock E.D.; Acharya K.R.; Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme. Sci Rep 2015,5,13742","journal-title":"Sci Rep"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1021\/acs.jmedchem.7b01478","volume":"61","author":"Fienberg S.","year":"2018","unstructured":"Fienberg S.; Cozier G.E.; Acharya K.R.; Chibale K.; Sturrock E.D.; The design and development of a potent and selective novel diprolyl derivative that binds to the N-domain of angiotensin-i converting enzyme. J Med Chem 2018,61(1),344-359","journal-title":"J Med Chem"},{"key":"ref=49","first-page":"8963","volume":"39","author":"Coates D.","year":"2000","unstructured":"Coates D.; Isaac R.E.; Cotton J.; Siviter R.; Williams T.A.; Shirras A.; Corvol P.; Dive V.; Functional conservation of the active sites of human and Drosophila angiotensin I-converting enzyme. Biochemistry 2000,39(30),8963-8969","journal-title":"Biochemistry"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S0014-5793(03)00128-5","volume":"538","author":"Kim H.M.","year":"2003","unstructured":"Kim H.M.; Shin D.R.; Yoo O.J.; Lee H.; Lee J.O.; Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. FEBS Lett 2003,538(1-3),65-70","journal-title":"FEBS Lett"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jmb.2010.05.024","volume":"400","author":"Akif M.","year":"2010","unstructured":"Akif M.; Georgiadis D.; Mahajan A.; Dive V.; Sturrock E.D.; Isaac R.E.; Acharya K.R.; High-resolution crystal structures of Drosophila melanogaster angiotensin-converting enzyme in complex with novel inhibitors and antihypertensive drugs. J Mol Biol 2010,400(3),502-517","journal-title":"J Mol Biol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.bbrc.2010.06.113","volume":"398","author":"Akif M.","year":"2010","unstructured":"Akif M.; Ntai I.; Sturrock E.D.; Isaac R.E.; Bachmann B.O.; Acharya K.R.; Crystal structure of a phosphonotripeptide K-26 in complex with angiotensin converting enzyme homologue (AnCE) from Drosophila melanogaster. Biochem Biophys Res Commun 2010,398(3),532-536","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1111\/febs.12038","volume":"279","author":"Akif M.","year":"2012","unstructured":"Akif M.; Masuyer G.; Bingham R.J.; Sturrock E.D.; Isaac R.E.; Acharya K.R.; Structural basis of peptide recognition by the angiotensin-1 converting enzyme homologue AnCE from Drosophila melanogaster. FEBS J 2012,279(24),4525-4534","journal-title":"FEBS J"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.fob.2015.08.004","volume":"5","author":"Harrison C.","year":"2015","unstructured":"Harrison C.; Acharya K.R.; A new high-resolution crystal structure of the Drosophila melanogaster angiotensin converting enzyme homologue, AnCE. FEBS Open Bio 2015,5,661-667","journal-title":"FEBS Open Bio"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"845","DOI":"10.2174\/092986712799034950","volume":"19","author":"Anthony C.S.","year":"2012","unstructured":"Anthony C.S.; Masuyer G.; Sturrock E.D.; Acharya K.R.; Structure based drug design of angiotensin-I converting enzyme inhibitors. Curr Med Chem 2012,19(6),845-855","journal-title":"Curr Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1080\/1062936X.2018.1485737","volume":"29","author":"Stoi\u010dkov V.","year":"2018","unstructured":"Stoi\u010dkov V.; \u0160ari\u0107 S.; Golubovi\u0107 M.; Zlatanovi\u0107 D.; Krtini\u0107 D.; Dini\u0107 L.; Mladenovi\u0107 B.; Sokolovi\u0107 D.; Veselinovi\u0107 A.M.; Development of non-peptide ACE inhibitors as novel and potent cardiovascular therapeutics: An in silico modelling approach. SAR QSAR Environ Res 2018,29(7),503-515","journal-title":"SAR QSAR Environ Res"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1042\/bj3210265","volume":"321","author":"Hooper N.M.","year":"1997","unstructured":"Hooper N.M.; Karran E.H.; Turner A.J.; Membrane protein secretases. Biochem J 1997,321(Pt 2),265-279","journal-title":"Biochem J"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.bbrc.2016.10.155","volume":"481","author":"Conrad N.","year":"2016","unstructured":"Conrad N.; Schwager S.L.; Carmona A.K.; Sturrock E.D.; The effect of structural motifs on the ectodomain shedding of human angiotensin-converting enzyme. Biochem Biophys Res Commun 2016,481(1-2),111-116","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1042\/bj3580185","volume":"358","author":"Pang S.","year":"2001","unstructured":"Pang S.; Chubb A.J.; Schwager S.L.; Ehlers M.R.; Sturrock E.D.; Hooper N.M.; Roles of the juxtamembrane and extracellular domains of angiotensin-converting enzyme in ectodomain shedding. Biochem J 2001,358(Pt 1),185-192","journal-title":"Biochem J"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1021\/bi00439a001","volume":"28","author":"Ehlers M.R.","year":"1989","unstructured":"Ehlers M.R.; Riordan J.F.; Angiotensin-converting enzyme: New concepts concerning its biological role. Biochemistry 1989,28(13),5311-5318","journal-title":"Biochemistry"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1515\/BC.2008.131","volume":"389","author":"O\u2019Neill H.G.","year":"2008","unstructured":"O\u2019Neill H.G.; Redelinghuys P.; Schwager S.L.; Sturrock E.D.; The role of glycosylation and domain interactions in the thermal stability of human angiotensin-converting enzyme. Biol Chem 2008,389(9),1153-1161","journal-title":"Biol Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1021\/cs500093h","volume":"4","author":"Br\u00e1s N.E.","year":"2014","unstructured":"Br\u00e1s N.E.; Fernandes P.A.; Ramos M.J.; QM\/MM Study and MD Simulations on the Hypertension Regulator Angiotensin-Converting Enzyme. ACS Catal 2014,4(8),2587-2597","journal-title":"ACS Catal"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/protein\/gzg122","volume":"16","author":"Tzakos A.G.","year":"2003","unstructured":"Tzakos A.G.; Galanis A.S.; Spyroulias G.A.; Cordopatis P.; Manessi-Zoupa E.; Gerothanassis I.P.; Structure-function discrimination of the N- and C-catalytic domains of human angiotensin-converting enzyme: implications for Cl- activation and peptide hydrolysis mechanisms. Protein Eng 2003,16(12),993-1003","journal-title":"Protein Eng"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1515\/hsz-2014-0157","volume":"395","author":"Masuyer G.","year":"2014","unstructured":"Masuyer G.; Yates C.J.; Sturrock E.D.; Acharya K.R.; Angiotensin-I converting enzyme (ACE): structure, biological roles, and molecular basis for chloride ion dependence. Biol Chem 2014,395(10),1135-1149","journal-title":"Biol Chem"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","volume":"27","author":"Schechter I.","year":"1967","unstructured":"Schechter I.; Berger A.; On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun 1967,27(2),157-162","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1093\/ajhp\/57.suppl_1.S3","volume":"57","author":"Piepho R.W.","year":"2000","unstructured":"Piepho R.W.; Overview of the angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm 2000,57(Suppl. 1),S3-S7","journal-title":"Am J Health Syst Pharm"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.drudis.2014.06.026","volume":"19","author":"Regulska K.","year":"2014","unstructured":"Regulska K.; Stanisz B.; Regulski M.; Murias M.; How to design a potent, specific, and stable angiotensin-converting enzyme inhibitor. Drug Discov Today 2014,19(11),1731-1743","journal-title":"Drug Discov Today"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"4612","DOI":"10.1016\/j.bmcl.2006.06.003","volume":"16","author":"Nchinda A.T.","year":"2006","unstructured":"Nchinda A.T.; Chibale K.; Redelinghuys P.; Sturrock E.D.; Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors. Bioorg Med Chem Lett 2006,16(17),4612-4615","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"8405","DOI":"10.1021\/bi9011226","volume":"48","author":"Kr\u00f6ger W.L.","year":"2009","unstructured":"Kr\u00f6ger W.L.; Douglas R.G.; O\u2019Neill H.G.; Dive V.; Sturrock E.D.; Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme. Biochemistry 2009,48(35),8405-8412","journal-title":"Biochemistry"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12079-014-0236-8","volume":"8","author":"Harrison C.","year":"2014","unstructured":"Harrison C.; Acharya K.R.; ACE for all - a molecular perspective. J Cell Commun Signal 2014,8(3),195-210","journal-title":"J Cell Commun Signal"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0165-6147(03)00196-2","volume":"24","author":"Brew K.","year":"2003","unstructured":"Brew K.; Structure of human ACE gives new insights into inhibitor binding and design. Trends Pharmacol Sci 2003,24(8),391-394","journal-title":"Trends Pharmacol Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"4330","DOI":"10.1073\/pnas.96.8.4330","volume":"96","author":"Dive V.","year":"1999","unstructured":"Dive V.; Cotton J.; Yiotakis A.; Michaud A.; Vassiliou S.; Jiracek J.; Vazeux G.; Chauvet M.T.; Cuniasse P.; Corvol P.; RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites. Proc Natl Acad Sci USA 1999,96(8),4330-4335","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=73","first-page":"606","volume":"297","author":"Junot C.","year":"2001","unstructured":"Junot C.; Gonzales M.F.; Ezan E.; Cotton J.; Vazeux G.; Michaud A.; Azizi M.; Vassiliou S.; Yiotakis A.; Corvol P.; Dive V.; RXP 407, a selective inhibitor of the N-domain of angiotensin I-converting enzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis. J Pharmacol Exp Ther 2001,297(2),606-611","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"8048","DOI":"10.1021\/bi049504q","volume":"43","author":"Georgiadis D.","year":"2004","unstructured":"Georgiadis D.; Cuniasse P.; Cotton J.; Yiotakis A.; Dive V.; Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry 2004,43(25),8048-8054","journal-title":"Biochemistry"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"3941","DOI":"10.1111\/febs.13900","volume":"283","author":"Lubbe L.","year":"2016","unstructured":"Lubbe L.; Sewell B.T.; Sturrock E.D.; The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition. FEBS J 2016,283(21),3941-3961","journal-title":"FEBS J"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1517\/14740338.5.6.739","volume":"5","author":"Ehlers M.R.","year":"2006","unstructured":"Ehlers M.R.; Safety issues associated with the use of angiotensin-converting enzyme inhibitors. Expert Opin Drug Saf 2006,5(6),739-740","journal-title":"Expert Opin Drug Saf"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"15946","DOI":"10.1074\/jbc.M400149200","volume":"279","author":"Fuchs S.","year":"2004","unstructured":"Fuchs S.; Xiao H.D.; Cole J.M.; Adams J.W.; Frenzel K.; Michaud A.; Zhao H.; Keshelava G.; Capecchi M.R.; Corvol P.; Bernstein K.E.; Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 2004,279(16),15946-15953","journal-title":"J Biol Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.2174\/138161209789271889","volume":"15","author":"Dive V.","year":"2009","unstructured":"Dive V.; Chang C.F.; Yiotakis A.; Sturrock E.D.; Inhibition of zinc metallopeptidases in cardiovascular disease--from unity to trinity, or duality? Curr Pharm Des 2009,15(31),3606-3621","journal-title":"Curr Pharm Des"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1046\/j.1365-2125.2003.01947.x","volume":"57","author":"Worthley M.I.","year":"2004","unstructured":"Worthley M.I.; Corti R.; Worthley S.G.; Vasopeptidase inhibitors: will they have a role in clinical practice? Br J Clin Pharmacol 2004,57(1),27-36","journal-title":"Br J Clin Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1021\/jm9010803","volume":"53","author":"Jullien N.","year":"2010","unstructured":"Jullien N.; Makritis A.; Georgiadis D.; Beau F.; Yiotakis A.; Dive V.; Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem 2010,53(1),208-220","journal-title":"J Med Chem"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s11906-015-0557-x","volume":"17","author":"Paulis L.","year":"2015","unstructured":"Paulis L.; Rajkovicova R.; Simko F.; New developments in the pharmacological treatment of hypertension: Dead-end or a glimmer at the horizon? Curr Hypertens Rep 2015,17(6),557","journal-title":"Curr Hypertens Rep"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1161\/01.HYP.0000054215.71691.16","volume":"41","author":"Campbell D.J.","year":"2003","unstructured":"Campbell D.J.; Vasopeptidase inhibition: A double-edged sword? Hypertension 2003,41(3),383-389","journal-title":"Hypertension"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S0009-9236(98)90075-3","volume":"64","author":"Wallis E.J.","year":"1998","unstructured":"Wallis E.J.; Ramsay L.E.; Hettiarachchi J.; Combined inhibition of neutral endopeptidase and angiotensin-converting enzyme by sampatrilat in essential hypertension. Clin Pharmacol Ther 1998,64(4),439-449","journal-title":"Clin Pharmacol Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1021\/acs.jcim.6b00524","volume":"56","author":"Sharma R.K.","year":"2016","unstructured":"Sharma R.K.; Espinoza-Moraga M.; Poblete H.; Douglas R.G.; Sturrock E.D.; Caballero J.; Chibale K.; The dynamic nonprime binding of sampatrilat to the C-domain of angiotensin-converting enzyme. J Chem Inf Model 2016,56(12),2486-2494","journal-title":"J Chem Inf Model"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/172107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T00:11:13Z","timestamp":1663459873000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/172107\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,26]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,8,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406415666190514081132","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-08-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}